Oak Thistle LLC Sells 4,113 Shares of Chemed Corporation $CHE

Key Points

• Oak Thistle LLC reduced its stake in Chemed by 69.2%, selling 4,113 shares in the quarter and leaving the firm with 1,834 shares valued at about $785,000 per its latest 13F filing.
• Chemed missed quarterly expectations, reporting $6.42 EPS versus a $7.02 consensus and revenue of $639.34M versus $659.09M, while issuing FY2026 guidance of 23.25–24.25 EPS.
• Company insiders and analysts have been active: CEO Kevin McNamara sold 2,000 shares (~$806k), several brokers cut ratings/targets, and the consensus rating is currently Hold with an average target of $498 while the stock trades around $385.59.

Oak Thistle LLC cut its holdings in shares of Chemed Corporation (NYSE:CHE - Free Report) by 69.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,834 shares of the company's stock after selling 4,113 shares during the quarter. Oak Thistle LLC's holdings in Chemed were worth $785,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in CHE. Smartleaf Asset Management LLC boosted its position in Chemed by 71.4% during the third quarter. Smartleaf Asset Management LLC now owns 60 shares of the company's stock worth $27,000 after purchasing an additional 25 shares during the period. First Horizon Corp acquired a new position in shares of Chemed in the third quarter valued at $31,000. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Chemed in the third quarter valued at about $45,000. HM Payson & Co. lifted its stake in shares of Chemed by 35.5% during the 3rd quarter. HM Payson & Co. now owns 103 shares of the company's stock worth $46,000 after buying an additional 27 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Chemed by 330.4% during the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock worth $61,000 after buying an additional 76 shares during the last quarter. Institutional investors and hedge funds own 95.85% of the company's stock.

Chemed Stock Down 1.3%

Shares of Chemed stock opened at $385.59 on Friday. Chemed Corporation has a 12-month low of $365.20 and a 12-month high of $604.91. The company has a market capitalization of $5.63 billion, a price-to-earnings ratio of 20.99, a PEG ratio of 1.55 and a beta of 0.49. The firm's 50-day moving average price is $416.46 and its two-hundred day moving average price is $430.72.

Chemed (NYSE:CHE - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $6.42 EPS for the quarter, missing the consensus estimate of $7.02 by ($0.60). Chemed had a net margin of 10.48% and a return on equity of 25.66%. The firm had revenue of $639.34 million during the quarter, compared to analyst estimates of $659.09 million. During the same quarter in the previous year, the firm posted $6.83 earnings per share. Chemed's quarterly revenue was down .1% compared to the same quarter last year. Chemed has set its FY 2026 guidance at 23.250-24.250 EPS. On average, sell-side analysts expect that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 13th. Shareholders of record on Monday, February 23rd were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, February 23rd. Chemed's payout ratio is currently 13.06%.

Insiders Place Their Bets

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm's stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $403.18, for a total value of $806,360.00. Following the sale, the chief executive officer owned 93,719 shares of the company's stock, valued at approximately $37,785,626.42. This trade represents a 2.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently commented on CHE shares. Jefferies Financial Group lowered shares of Chemed from a "buy" rating to a "hold" rating in a research note on Thursday, January 22nd. Oppenheimer cut their price objective on shares of Chemed from $580.00 to $500.00 and set an "outperform" rating for the company in a research report on Friday, February 27th. Royal Bank Of Canada restated a "sector perform" rating and set a $422.00 price objective (down from $572.00) on shares of Chemed in a report on Friday, February 27th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Chemed in a research report on Wednesday, January 21st. Finally, Zacks Research lowered Chemed from a "hold" rating to a "strong sell" rating in a research note on Wednesday, March 4th. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $498.00.

Chemed Profile

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.